Latest Commercialization News

Dimerix Limited has completed dosing of the last adult patient in its ACTION3 Phase 3 trial for DMX-200, exceeding its recruitment target and setting the stage for key regulatory milestones.

Tetratherix Limited has raised approximately $5 million to fast-track its Tutelix prostate spacer into pivotal clinical trials across Australia and the US, aiming to improve radiation therapy for prostate cancer patients.

Orthocell has appointed LEDA Orthopaedics as the exclusive distributor for its Remplir™ nerve repair product in the UK, positioning itself for a rapid commercial launch pending regulatory approval.

Clarity Pharmaceuticals has completed enrolment in its Phase III AMPLIFY trial for the Cu-SAR-bisPSMA imaging agent, advancing its bid for FDA approval in prostate cancer diagnostics.

Mammoth Minerals has secured an exclusive option to acquire the historic Imperial Gold Mine near its Excelsior Springs project in Nevada, significantly expanding its landholding and exploration potential in a prolific gold district.

ABx Group has discovered new high-extraction ionic rare earth zones at its Deep Leads project in Tasmania, accelerating the path to production within months of approval. This breakthrough enhances the project's commercial viability with rare earths critical for green technologies.

Metallium Limited reports rapid progress at its Gator Point Technology Campus in Texas, advancing its proprietary Flash Joule Heating technology to recover critical metals from electronic waste. The company targets processing 8,000 tonnes of printed circuit boards annually by late 2026.

EVE Health Group has completed R&D on multiple reformulated drug candidates targeting major sexual health and cardiovascular markets, preparing patent filings and licensing strategies to capitalise on a combined $30 billion global opportunity.

BPM Minerals has resumed exploration at its Forelands Gold Project in WA, launching a 7,500m drilling campaign at Beachcomber and advancing Bonnie & Clyde towards maiden drilling. The project shows strong potential for a Tropicana-style gold discovery.

Hubify has provided detailed terms of its $250,000 equity investment in Australian AI firm HubLab, reinforcing its AI-first growth ambitions targeting enterprise and government sectors.

Cyclopharm Limited has responded to ASX queries clarifying the material significance of its Technegas® contract with the US National Institutes of Health, while confirming robust progress in expanding its US footprint.

BluGlass has embarked on a A$1.25 million development program with a major US defence prime, receiving an initial A$560,000 order to develop cutting-edge visible GaN lasers for aerospace and defence applications.